Clinical Trial Update: Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Doxil (liposomal doxorubicin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED